Announced
Completed
AstraZeneca completed the acquisition of SixPeaks Bio for $300m.
Synopsis
AstraZeneca, a research-based bio-pharmaceutical company, completed the acquisition of SixPeaks Bio, a company developing mAb-peptide-based polyfunctional products, for $300m.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite